ONCOARENDI THERAPEUTICS
OncoArendi Therapeutics specialized in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.
ONCOARENDI THERAPEUTICS
Industry:
Alternative Medicine Biotechnology Emergency Medicine Medical
Founded:
2012-01-01
Address:
Wysokie Mazowieckie, Podlaskie, Poland
Country:
Poland
Website Url:
http://www.oncoarendi.com
Total Employee:
101+
Status:
Active
Total Funding:
60.6 M PLN
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apple Mobile Web Clips Icon Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Facebook Sharer
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Stock Details
Investors List
New Europe Ventures, LLC
New Europe Ventures, LLC investment in Series A - OncoArendi Therapeutics
Michał Sołowow
Michał Sołowow investment in Series A - OncoArendi Therapeutics
National Center for Research & Development
National Center for Research & Development investment in Grant - OncoArendi Therapeutics
Medical University of Warsaw
Medical University of Warsaw investment in Grant - OncoArendi Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-27 | OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.oncoarendi.com
- Host name: shared-aky43.rev.nazwa.pl
- IP address: 85.128.156.43
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "OncoArendi Therapeutics"
OncoArendi Therapeutics - Crunchbase Company Profile & Funding
OncoArendi Therapeutics is a biopharmaceutical company devoted to finding, creating, and marketing treatments for inflammatory and cancerous conditions. The Company's business …See details»
Molecure
On the 28th March 2022, OncoArendi changed its name to Molecure. Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and …See details»
OncoArendi Therapeutics - Craft
Mar 25, 2022 OncoArendi Therapeutics is a biotech company focused on discovery and development of small molecule drug candidates. It studies the therapeutic potential of …See details»
OncoArendi Therapeutics Gets Listed - Molecure
OncoArendi Therapeutics S.A., an innovative, clinical stage, biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for cancer and …See details»
OncoArendi Therapeutics Information - RocketReach
OncoArendi Therapeutics is a biotech, public company based in Poland focused on discovery & development of small molecules to treat patients with unmet medical needs. OncoArendi …See details»
OncoArendi Therapeutics S.A. (WSE: OAT) - Life-Sciences …
Apr 1, 2018 OncoArendi Therapeutics Sp. z o.o. (OAT) Successor: Molecure S.A. (WSE: MOC) Industry: cancer immunotherapy (immuno-oncology, I-O) Industry 2: immunotherapy: Person: …See details»
Molecure (Group) - Life-Sciences-Europe.com
Mar 28, 2022 OncoArendi (Group) Industry: cancer immunotherapy (immuno-oncology, I-O) Industry 2: immunotherapy: Person: Szumowski, Marcin (OncoArendi 202011 CEO) Person 2: …See details»
Oncoarendi - Products, Competitors, Financials, Employees, …
Molecure, formerly known as OncoArendi, is an innovative biopharmaceutical company focused on the discovery and development of first-in-class small molecule drugs for the treatment of …See details»
OncoArendi Therapeutics - Funding, Financials, Valuation
OncoArendi Therapeutics is registered under the ticker WSE:OAT . Their stock opened with PLN29.00 in its Apr 19, 2018 IPO. Stock Symbol WSE:OAT ; Valuation at IPO PLN400M; …See details»
OncoArendi Therapeutics - Contacts, Employees, Board
OncoArendi Therapeutics specializes in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.See details»
INVESTOR & ANALYST PRESENTATION - Molecure
Nov 4, 2021 Potential milestone from OncoArendi and GLPG collaboration / license agreement In-licensing of one or more programs (1-2 years from IND) in core disease areas Attracting …See details»
OncoArendi Therapeutics CEO and Key Executive Team - Craft
OncoArendi Therapeutics's President of the Board, Chief Executive Officer is Marcin Szumowski. Other executives include Krzysztof Laskowski, Chairman of the Supervisory Board; SÅ‚awomir …See details»
Ardigen and OncoArendi join forces for research collaboration
Apr 15, 2021 In 2020, OncoArendi successfully completed clinical phase 1 for the drug candidate OATD-01 – a dual chitinase inhibitor. In November 2020, OncoArendi signed the …See details»
OncoArendi Therapeutics Reports Continued Strategic and
Mar 25, 2022 OncoArendi has an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 …See details»
OncoArendi Therapeutics to Begin the Phase 1 ... - World Pharma …
OncoArendi Therapeutics is an innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for inflammatory diseases associated with tissue …See details»
OncoArendi Therapeutics Reports Continued Strategic and …
Mar 25, 2022 Marcin Szumowski, CEO and President of the Management Board of OncoArendi commented: "We have made excellent progress during 2021 on key strategic initiatives …See details»
OncoArendi Therapeutics is significantly moving closer to the start …
Feb 8, 2022 OncoArendi has received scientific advice from the European Medicines Agency (EMA) on the clinical development of OATD-02 and has signed an agreement with BIOMAPAS …See details»
Organization and comprehensive execution of the phase I
E-mail: [email protected] phone no. +48 573 900 610 Kinga Kazimierczak e-mail: [email protected] Anna Bajera e-mail: [email protected] phone no. …See details»
OncoArendi executes the strategy for 2021-2025 in the area
Importantly, research at IIMCB is carried out at all levels of biological organization, i.e. from atoms and molecules, through cells and tissues, to entire organisms. IIMCB implements a long-term …See details»
OncoArendi Therapeutics - Molecure
OncoArendi Therapeutics Good dealmaker OncoArendi’s share price has risen 131% in the last 12M fueled by signing of a partnering agreement with Galapagos in the OATD-01/GLPG4716 …See details»